Exclusive Summary

• - PMDA-GMP backed dried amniotic membrane with room‑temperature stability fits device/tissue pathways in many countries, enabling fast scale-up.
• - Addresses both ocular surface reconstruction and chronic hard-to-heal wounds with ≥15 million potential patients/year (DFU ~10–11M, microbial keratitis ~1.5–2.0M, a subset of 11M burns).
• - Recognized by multiple guidelines as an effective adjunct (early use in acute ocular burns/epithelial defects; after 4–6 weeks of failed standard care in chronic wounds).
• - Crowded market but clear differentiation levers (dry RT-stable format, sterilization method, SKUs, supply reliability, tech transfer) create entry opportunities.
• - Expected 40–70% price advantage versus US/EU brands plus 10–20% savings from avoiding cold chain.

Asset Materials

Contact Us for Full Materials